- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for XOMA Corp (XOMA)
| Open: | 4.1000 | Day's Range: | 3.9750 - 4.1300 | Volume: | 435,522 |
|---|---|---|---|---|---|
| Previous Close: | 4.0900 | 52wk Range: | 2.2500 - 4.4000 | 1-Yr Rtn: | +71.85% |
Key Statistics for XOMA
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.7800 |
| Est. EPS (USD) (12/2013) | -0.8490 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 339.03 |
| Shares Outstanding (M) | 82.89 |
| 30 Day Average Volume | 793,058 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | 9.0458 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/07/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for XOMA
Company Profile & Key Executives for XOMA
XOMA Corporation is a biopharmaceutical company that develops and manufactures genetically engineered protein, peptide, and antibody pharmaceuticals. The Company's medical targets include bacterial and fungal infections, infectious complications, and immunologic and inflammatory disorders. XOMA's primary drug development platform is bactericidal/permeability-increasing protein.
| John VarianChief Executive Officer | Patrick J ScannonExec VP/Chief Scientific Ofcr |
| Paul D RubinSenior VP:Research & Dev | Fred KurlandVP:Finance/CFO/Secretary |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
XOMA News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page